Huluka Dawit Kebede, Mekonnen Desalew, Abebe Sintayehu, Meshesha Amha, Mekonnen Dufera, Deyessa Negussie, Klinger James R, Ventetuolo Corey E, Schluger Neil W, Sherman Charles B, Amogne Wondwossen
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Heath Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Division of Cardiology, Department of Internal Medicine, College of Heath Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Pulm Circ. 2020 Nov 25;10(4):2045894020971518. doi: 10.1177/2045894020971518. eCollection 2020 Oct-Dec.
Globally, non-communicable diseases are increasing in people living with HIV. Pulmonary hypertension is a rare non-communicable disease in people living with HIV with a reported prevalence of <1%. However, data on pulmonary hypertension in people living with HIV from Africa are scarce and are non-existent from Ethiopia. This study aimed to examine the prevalence and severity of echocardiographic pulmonary hypertension and risk factors associated with pulmonary hypertension in people living with HIV in Ethiopia. A total of 315 consecutive adult people living with HIV followed at the Tikur Anbessa Specialized Hospital HIV Referral Clinic were enrolled from June 2018 to February 2019. Those with established pulmonary hypertension of known causes were excluded. A structured questionnaire was used to collect data on demographics, respiratory symptoms, physical findings, physician-diagnosed lung disease, and possible risk factors. Pulmonary hypertension was defined by a tricuspid regurgitant velocity of ≥2.9 m/sec on transthoracic echocardiography. A tricuspid regurgitant velocity ≥3.5, which translates into a pulmonary arterial pressure/right ventricular systolic pressure of ≥50 mmHg, was considered moderate-to-severe pulmonary hypertension. The mean age of the participants was 44.5 ± 9.8 years and 229 (72.7%) were females. Pulmonary hypertension was diagnosed in 44 (14.0%) of participants, of whom 9 (20.5%) had moderate-to-severe disease. In those with pulmonary hypertension, 17 (38.6%) were symptomatic: exertional dyspnea, cough, and leg swelling were seen in 12 (27.3%), 9 (20.5%), and 4 (9.1%), respectively. There was no significant difference in those with pulmonary hypertension compared to those without the disease by gender, cigarette smoking, previous history of pulmonary tuberculosis treatment, physician-diagnosed chronic obstructive pulmonary disease or bronchial asthma, duration of anti-retroviral therapy therapy or anti-retroviral regimen type. Pulmonary hypertension looks to be a frequent complication in people living with HIV in Ethiopia and is often associated with significant cardiopulmonary symptoms. Further studies using right heart catheterization are needed to better determine the etiology and prevalence of pulmonary hypertension in people living with HIV in Ethiopia compared to other countries.
在全球范围内,艾滋病毒感染者中非传染性疾病的发病率正在上升。肺动脉高压在艾滋病毒感染者中是一种罕见的非传染性疾病,据报道患病率<1%。然而,来自非洲的艾滋病毒感染者肺动脉高压的数据稀缺,埃塞俄比亚则尚无此类数据。本研究旨在调查埃塞俄比亚艾滋病毒感染者中超声心动图诊断的肺动脉高压的患病率、严重程度以及与肺动脉高压相关的危险因素。2018年6月至2019年2月,从提库尔·安贝萨专科医院艾滋病毒转诊诊所连续纳入315名成年艾滋病毒感染者。排除已知病因的已确诊肺动脉高压患者。使用结构化问卷收集人口统计学、呼吸道症状、体格检查结果、医生诊断的肺部疾病以及可能的危险因素的数据。经胸超声心动图检查三尖瓣反流速度≥2.9米/秒定义为肺动脉高压。三尖瓣反流速度≥3.5,即肺动脉压/右心室收缩压≥50毫米汞柱,被视为中度至重度肺动脉高压。参与者的平均年龄为44.5±9.8岁,229名(72.7%)为女性。44名(14.0%)参与者被诊断为肺动脉高压,其中9名(20.5%)患有中度至重度疾病。在患有肺动脉高压的患者中,17名(38.6%)有症状:运动性呼吸困难、咳嗽和腿部肿胀分别见于12名(27.3%)、9名(20.5%)和4名(9.1%)。在性别、吸烟、既往肺结核治疗史、医生诊断的慢性阻塞性肺疾病或支气管哮喘、抗逆转录病毒治疗持续时间或抗逆转录病毒治疗方案类型方面,患有肺动脉高压的患者与未患该疾病的患者之间没有显著差异。肺动脉高压似乎是埃塞俄比亚艾滋病毒感染者中的常见并发症,且常伴有明显的心肺症状。与其他国家相比,需要进一步采用右心导管检查的研究来更好地确定埃塞俄比亚艾滋病毒感染者肺动脉高压的病因和患病率。